213 A Phase Ii Study of Etanercept (ENBREL), A Tumour Necrosis Factor-Alpha Inhibitor in Recurrent Ovarian Cancer
Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust), Trivadi S. Ganesan(Churchill Hospital), S. Wilner, Jeremy Braybrooke(University Hospitals Bristol NHS Foundation Trust), Chengcheng Han(Asia Pacific Center for Theoretical Physics), S. Muthuramalingam(Churchill Hospital), Frances R. Balkwill(Queen Mary University of London), S F Hoare(Queen Mary University of London), Kanchan Kaur(Churchill Hospital)
Cited by 1
Related Papers
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
“Re-educating” tumor-associated macrophages by targeting NF-κB
|The Journal of Experimental Medicine|2008|780